Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Quadriga Biosciences Inc. maintains a streamlined prosecution profile in the Biotechnology & Pharmaceuticals sector. The company currently has 1 pending office action, which is being handled by 1 distinct examiner. This prosecution activity is contained within 1 distinct art unit, reflecting a focused technical scope for the pending application.
SCHLIENTZ, LEAH H serves as the busiest examiner for the portfolio. This examiner is currently managing 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this single examiner oversees the company's entire active docket at the USPTO. The fact that there is only 1 distinct examiner involved suggests a specific technological focus for the company's current intellectual property efforts. Practitioners must tailor their approach to the specific preferences of SCHLIENTZ, LEAH H to successfully navigate the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, LEAH H | 1 | 41.8% | +38.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18216888 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | SCHLIENTZ, LEAH H | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18216888 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuadriga Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Leah H Schlientz has the most, with 1 of Quadriga Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
